New Tools for Cardiovascular Risk Stratification;Nuevas herramientas en la estratificación del riesgo cardiovascular

Revista Espanola de Cardiologia Suplementos

Volumn 11, Issue 2, 2011, Pages 21-28

  Badimón, Juan José ^a   Santos Gallego, Carlos G ^a   Torres, Francisco ^b   Castillo, Jesús ^c   Kaski, Juan Carlos ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

C reactive protein; Cost benefit analysis; Diagnosis; Low density lipoproteins; Magnetic resonance imaging; Molecular medicine; Myocardial infarction; Natriuretic peptides; Prognosis; Risk factors; Stroke; Tomography

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; ATHEROSCLEROSIS; CARDIAC IMAGING; CARDIOVASCULAR RISK; CLINICAL FEATURE; HUMAN; SCORING SYSTEM; THERAPY EFFECT;

EID: 84866759272     PISSN: 11313587     EISSN: 15792250     Source Type: Journal    
DOI: 10.1016/S1131-3587(11)12004-X     Document Type: Article

References (103)

1. Gibbons R.J., Jones D.W., Gardner T.J., Goldstein L.B., Moller J.H., Yancy C.W. The American Heart Association's 2008 Statement of Principles for Healthcare Reform. Circulation 2008, 118:2209-2218.
2. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
3. Empana J.P., Ducimetiere P., Arveiler D., Ferrieres J., Evans A., Ruidavets J.B., et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003, 24:1903-1911.
4. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
5. Marrugat J., Solanas P., D'Agostino R., Sullivan L., Ordovas J., Cordón F., et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol 2003, 56:253-261.
6. Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007, 297:611-619.
7. Cooney M.T., Dudina A., D'Agostino R., Graham I.M. Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future?. Circulation 2010, 122:300-310.
8. Grau M., Marrugat J. Funciones de riesgo en la prevención primaria de las enfermedades cardiovasculares. Rev Esp Cardiol 2008, 61:404-416.
9. Lauer M.S. Screening asymptomatic subjects for subclinical atherosclerosis: not so obvious. J Am Coll Cardiol 2010, 56:106-108.
10. Shah P.K. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we?. J Am Coll Cardiol 2010, 56:98-105.
11. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
12. Calabro P., Golia E., Yeh E.T. CRP and the risk of atherosclerotic events. Semin Immunopathol 2009, 31:79-94.
13. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
14. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
15. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
16. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
17. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182.
18. Sabatine M.S., Morrow D.A., Jablonski K.A., Rice M.M., Warnica J.W., Domanski M.J., et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007, 115:1528-1536.
19. Arroyo-Espliguero R., Avanzas P., Quiles J., Kaski J.C. C-reactive protein predicts functional status and correlates with left ventricular ejection fraction in patients with chronic stable angina. Atherosclerosis 2009, 205:319-324.
20. Zouridakis E., Avanzas P., Arroyo-Espliguero R., Fredericks S., Kaski J.C. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004, 110:1747-1753.
21. Foussas S.G., Zairis M.N., Lyras A.G., Patsourakos N.G., Tsirimpis V.G., Katsaros K., et al. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes. Am J Cardiol 2005, 96:533-537.
22. Bogaty P., Boyer L., Simard S., Dauwe F., Dupuis R., Verret B., et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol 2008, 51:2339-2346.
23. Kaski J.C., Fernandez-Berges D.J., Consuegra-Sanchez L., Fernandez J.M., Garcia-Moll X., Mostaza J.M., et al. A comparative study of biomarkers for risk prediction in acute coronary syndrome-Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. Atherosclerosis 2010, 212:636-643.
24. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl 2):S1-S113.
25. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
26. Genest J., McPherson R., Frohlich J., Anderson T., Campbell N., Carpentier A., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009, 25:567-579.
27. Sever P.S.P.N., Chang C.L., Thom S.A.M., Hughes A.D., Welsh P., Sattar N., The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Testing C-reactive protein at baseline and on-treatment as an independent predictor of cardiovascular outcomes. American Heart Association 2010 Scientific Sessions; 2010 November 13-17, 2010 2010, Chicago, IL, USA.
28. Kaski J.C., Consuegra-Sanchez L., Fernandez-Berges D.J., Cruz-Fernandez J.M., Garcia-Moll X., Marrugat J., et al. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis 2008, 201:176-183.
29. Ray K.K., Morrow D.A., Sabatine M.S., Shui A., Rifai N., Cannon C.P., et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007, 115:3071-3078.
30. Thompson A., Gao P., Orfei L., Watson S., Di Angelantonio E., Kaptoge S., et al. Lipoproteinassociated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544.
31. Cesari M., Penninx B.W., Newman A.B., Kritchevsky S.B., Nicklas B.J., Sutton-Tyrrell K., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108:2317-2322.
32. Troseid M., Seljeflot I., Hjerkinn E.M., Arnesen H. Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care 2009, 32:486-492.
33. Fisman E.Z., Benderly M., Esper R.J., Behar S., Boyko V., Adler Y., et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 2006, 98:14-18.
34. Biasucci L.M., Liuzzo G., Fantuzzi G., Caligiuri G., Rebuzzi A.G., Ginnetti F., et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999, 99:2079-2084.
35. Blankenberg S., Tiret L., Bickel C., Peetz D., Cambien F., Meyer J., et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002, 106:24-30.
36. Malik I., Danesh J., Whincup P., Bhatia V., Papacosta O., Walker M., et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001, 358:971-976.
37. Danesh J. Antibiotics in the prevention of heart attacks. Lancet 2005, 365:365-367.
38. Yan R.T., Fernandes V., Yan A.T., Cushman M., Redheuil A., Tracy R., et al. Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2010, 160:479-486.
39. Bahrami H., Bluemke D.A., Kronmal R., Bertoni A.G., Lloyd-Jones D.M., Shahar E., et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008, 51:1775-1783.
40. Paraskevas K.I., Baker D.M., Vrentzos G.E., Mikhailidis D.P. The role of fibrinogen and fibrinolysis in peripheral arterial disease. Thromb Res 2008, 122:1-12.
41. Toss H., Lindahl B., Siegbahn A., Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997, 96:4204-4210.
42. Piechota M., Banach M., Jacon A., Rysz J. Natriuretic peptides in cardiovascular diseases. Cell Mol Biol Lett 2008, 13:155-181.
43. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Omland T., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663.
44. James S.K., Lindahl B., Siegbahn A., Stridsberg M., Venge P., Armstrong P., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003, 108:275-281.
45. Hillege H.L., Fidler V., Diercks G.F., Van Gilst W.H., De Zeeuw D., Van Veldhuisen D.J., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106:1777-1782.
46. Berton G., Cordiano R., Palmieri R., Cucchini F., De Toni R., Palatini P. Microalbuminuria during acute myocardial infarction; a strong predictor for 1-year mortality. Eur Heart J 2001, 22:1466-1475.
47. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S.L., Newman A.B., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005, 352:2049-2060.
48. Tousoulis D., Kampoli A.M., Stefanadi E., Antoniades C., Siasos G., Papavassiliou A.G., et al. New biochemical markers in acute coronary syndromes. Curr Med Chem 2008, 15:1288-1296.
49. Ohman E.M., Armstrong P.W., White H.D., Granger C.B., Wilcox R.G., Weaver W.D., et al. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol 1999, 84:1281-1286.
50. Ottani F., Galvani M., Nicolini F.A., Ferrini D., Pozzati A., Di Pasquale G., et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000, 140:917-927.
51. James S.K., Armstrong P., Barnathan E., Califf R., Lindahl B., Siegbahn A., et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GuSTO-IV substudy. J Am Coll Cardiol 2003, 41:916-924.
52. Keller T., Zeller T., Peetz D., Tzikas S., Roth A., Czyz E., et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009, 361:868-877.
53. Nair A., Kuban B.D., Tuzcu E.M., Schoenhagen P., Nissen S.E., Vince D.G. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002, 106:2200-2206.
54. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
55. Gonzalo N., Garcia-Garcia H.M., Regar E., Barlis P., Wentzel J., Onuma Y., et al. In vivo assessment of high-risk coronary plaques at bifurcations with combined intravascular ultrasound and optical coherence tomography. JACC Cardiovasc Imaging 2009, 2:473-482.
56. Howard G., Burke G.L., Evans G.W., Crouse J.R., Riley W., Arnett D., et al. Relations of intimal-medial thickness among sites within the carotid artery as evaluated by B-mode ultrasound. ARIC Investigators. Atherosclerosis Risk in Communities. Stroke 1994, 25:1581-1587.
57. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
58. Goldstein L.B., Adams R., Alberts M.J., Appel L.J., Brass L.M., Bushnell C.D., et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006, 37:1583-1633.
59. Screening for carotid artery stenosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007, 147:854-859.
60. Simon A., Megnien J.L., Chironi G. The value of carotid intima-media thickness for predicting cardiovascular risk. Arterioscler Thromb Vasc Biol 2010, 30:182-185.
61. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBiTeR) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
62. Taylor A.J., Villines T.C., Stanek E.J., Devine P.J., Griffen L., Miller M., et al. Extendedrelease niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
63. Budoff M.J., Shaw L.J., Liu S.T., Weinstein S.R., Mosler T.P., Tseng P.H., et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 2007, 49:1860-1870.
64. Raggi P., Gongora M.C., Gopal A., Callister T.Q., Budoff M., Shaw L.J. Coronary artery calcium to predict all-cause mortality in elderly men and women. J Am Coll Cardiol 2008, 52:17-23.
65. Greenland P., LaBree L., Azen S.P., Doherty T.M., Detrano R.C. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004, 291:210-215.
66. Rosen B.D., Fernandes V., McClelland R.L., Carr J.J., Detrano R., Bluemke D.A., et al. Relationship between baseline coronary calcium score and demonstration of coronary artery stenoses during follow-up MESA (Multi-Ethnic Study of Atherosclerosis). JACC Cardiovasc Imaging 2009, 2:1175-1183.
67. Sarwar A., Shaw L.J., Shapiro M.D., Blankstein R., Hoffman U., Cury R.C., et al. Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging 2009, 2:675-688.
68. Schenker M.P., Dorbala S., Hong E.C., Rybicki F.J., Hachamovitch R., Kwong R.Y., et al. Interrelation of coronary calcification, myocardial ischemia, and outcomes in patients with intermediate likelihood of coronary artery disease: a combined positron emission tomography/computed tomography study. Circulation 2008, 117:1693-1700.
69. Henneman M.M., Schuijf J.D., Pundziute G., Van Werkhoven J.M., Van der Wall E.E., Jukema J.W., et al. Noninvasive evaluation with multislice computed tomography in suspected acute coronary syndrome: plaque morphology on multislice computed tomography versus coronary calcium score. J Am Coll Cardiol 2008, 52:216-222.
70. McEvoy J.W., Blaha M.J., Defilippis A.P., Budoff M.J., Nasir K., Blumenthal R.S., et al. Coronary artery calcium progression: an important clinical measurement? A review of published reports. J Am Coll Cardiol 2010, 56:1613-1622.
71. Raggi P., Davidson M., Callister T.Q., Welty F.K., Bachmann G.A., Hecht H., et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 2005, 112:563-571.
72. Folsom A.R., Kronmal R.A., Detrano R.C., O'Leary D.H., Bild D.E., Bluemke D.A., et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2008, 168:1333-1339.
73. Detrano R., Guerci A.D., Carr J.J., Bild D.E., Burke G., Folsom A.R., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008, 358:1336-1345.
74. Newman A.B., Naydeck B.L., Sutton-Tyrrell K., Edmundowicz D., O'Leary D., Kronmal R., et al. Relationship between coronary artery calcification and other measures of subclinical cardiovascular disease in older adults. Arterioscler Thromb Vasc Biol 2002, 22:1674-1679.
75. Elias-Smale S.E., Proenca R.V., Koller M.T., Kavousi M., Van Rooij F.J., Hunink M.G., et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol 2010, 56:1407-1414.
76. Blaha MJ B.M., Defilippis A.P., Rivera J.J., Blankstein R., O'Leary D.H., Lima J., et al. Association between hsCRP≥2, Coronary Artery Calcium, and Adverse Events - Implications for the JUPITER Population: Multi-Ethnic Study of Atherosclerosis (MESA). American Heart Association 2010 Scientific Sessions 2010, Chicago, IL, USA.
77. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. ACC/ AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006, 113:e463-e654.
78. Doobay A.V., Anand S.S. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol 2005, 25:1463-1469.
79. Smith S.C., Greenland P., Grundy S.M., AHA Conference Proceedings Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation 2000, 101:111-116.
80. Fowkes F.G., Murray G.D., Butcher I., Heald C.L., Lee R.J., Chambless L.E., et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008, 300:197-208.
81. Eldrup N., Sillesen H., Prescott E., Nordestgaard B.G. Ankle brachial index, C-reactive protein, and central augmentation index to identify individuals with severe atherosclerosis. Eur Heart J 2006, 27:316-322.
82. Resnick H.E., Lindsay R.S., McDermott M.M., Devereux R.B., Jones K.L., Fabsitz R.R., et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004, 109:733-739.
83. Brunner H., Cockcroft J.R., Deanfield J., Donald A., Ferrannini E., Halcox J., et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005, 23:233-246.
84. Halcox J.P., Donald A.E., Ellins E., Witte D.R., Shipley M.J., Brunner E.J., et al. Endothelial function predicts progression of carotid intima-media thickness. Circulation 2009, 119:1005-1012.
85. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995, 332:481-487.
86. Frick M., Suessenbacher A., Alber H.F., Dichtl W., Ulmer H., Pachinger O., et al. Prognostic value of brachial artery endothelial function and wall thickness. J Am Coll Cardiol 2005, 46:1006-1010.
87. Shimbo D., Grahame-Clarke C., Miyake Y., Rodriguez C., Sciacca R., Di Tullio M., et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 2007, 192:197-203.
88. Yeboah J., Folsom A.R., Burke G.L., Johnson C., Polak J.F., Post W., et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a populationbased study: the multi-ethnic study of atherosclerosis. Circulation 2009, 120:502-509.
89. Yeboah J., Crouse J.R., Hsu F.C., Burke G.L., Herrington D.M. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007, 115:2390-2397.
90. Feinstein S.B. Contrast ultrasound imaging of the carotid artery vasa vasorum and atherosclerotic plaque neovascularization. J Am Coll Cardiol 2006, 48:236-243.
91. Granada J.F., Feinstein S.B. Imaging of the vasa vasorum. Nat Clin Pract Cardiovasc Med 2008, 5(Suppl 2):S18-S25.
92. Schuetz g.M., Zacharopoulou N.M., Schlattmann P., Dewey M. Meta-analysis: noninvasive coronary angiography using computed tomography versus magnetic resonance imaging. Ann Intern Med 2010, 152:167-177.
93. Motoyama S., Kondo T., Sarai M., Sugiura A., Harigaya H., Sato T., et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol 2007, 50:319-326.
94. Motoyama S., Sarai M., Harigaya H., Anno H., Inoue K., Hara T., et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 2009, 54:49-57.
95. Corti R., Fayad Z.A., Fuster V., Worthley S.G., Helft G., Chesebro J., et al. Effects of lipidlowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001, 104:249-252.
96. Corti R., Fuster V., Fayad Z.A., Worthley S.G., Helft G., Smith D., et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002, 106:2884-2887.
97. Corti R., Fuster V., Fayad Z.A., Worthley S.G., Helft G., Chaplin W.F., et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with highresolution magnetic resonance imaging. J Am Coll Cardiol 2005, 46:106-112.
98. Lee J.M., Robson M.D., Yu L.M., Shirodaria C.C., Cunnington C., Kylintireas I., et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009, 54:1787-1794.
99. Nahrendorf M., Keliher E., Panizzi P., Zhang H., Hembrador S., Figueiredo J.L., et al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging 2009, 2:1213-1222.
100. Fujimoto S., Hartung D., Ohshima S., Edwards D.S., Zhou J., Yalamanchili P., et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol 2008, 52:1847-1857.
101. Ruehm S.G., Corot C., Vogt P., Kolb S., Debatin J.F. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001, 103:415-422.
102. Matter C.M., Stuber M., Nahrendorf M. Imaging of the unstable plaque: how far have we got?. Eur Heart J 2009, 30:2566-2574.
103. Ibanez B., Badimon J.J., Garcia M.J. Diagnosis of atherosclerosis by imaging. Am J Med 2009, 122(1 Suppl):S15-S25.